Aptinyx Overview
- Founded
- 2015

- Status
- Public
- Employees
- 43

- Stock Symbol
- APTX

- Share Price
- $4.20
- (As of Wednesday Closing)
Aptinyx General Information
Description
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Contact Information
- 909 Davis Street
- Suite 600
- Evanston, IL 60201
- United States
Aptinyx Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.20 | $4.33 | $1.60 - $6.47 | $266M | 63.3M | 1M | -$1.26 |
Aptinyx Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 42,855 | 971 | 388,468 | |
Revenue | 2,482 | 3,669 | 6,574 | 4,962 |
EBITDA | (51,943) | (56,955) | (52,824) | (31,663) |
Net Income | (52,343) | (57,410) | (53,281) | (32,068) |
Total Assets | 114,207 | 106,479 | 155,614 | 97,322 |
Aptinyx Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.
Request a free trialAptinyx Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Aptinyx‘s full profile, request access.
Request a free trialAptinyx Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAptinyx Competitors (13)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alector | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Lexington, MA | 00 | 00000 | 000000000 | 00000 |
0000000 | Venture Capital-Backed | Framingham, MA | 00 | 0000 | 0000000000 | 0000 |
000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 000000&0 | 000.00 |
000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000 | 00000 |
Aptinyx Executive Team (10)
Aptinyx Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Adam Koppel MD | Bain Capital | Board Member | 000 0000 |
Henry Gosebruch | Self | Board Member | 000 0000 |
James Topper Ph.D | Frazier Healthcare Partners | Board Member | 000 0000 |
Norbert Riedel Ph.D | Aptinyx | Chief Executive Officer & Board Member | 000 0000 |
Patrick Enright | Longitude Capital | Chairman & Board Member | 000 0000 |
Aptinyx Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial